Ureteral Neoplasms clinical trials
The registry lists 79 studies for Ureteral Neoplasms across more than 10 countries. 17 are recruiting or about to start. 13 of them are mainly about Ureteral Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Ureteral Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (12) · Eli Lilly and Company (5) · M.D. Anderson Cancer Center (5) · Mayo Clinic (4) · Changhai Hospital (3) · Asan Medical Center (3) · Emory University (2) · Peking University First Hospital (2)
What is being tested here
Drugs under test in Ureteral Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Enfortumab vedotin | 1 | 1 | 5 |
| Pembrolizumab | 1 | 1 | 3 |
| Paclitaxel | 1 | 0 | 2 |
| Vepugratinib | 1 | 0 | 1 |
| Quemliclustat | 1 | 0 | 1 |
| Albumin-Bound Paclitaxel | 1 | 0 | 1 |
| Tamibarotene | 1 | 0 | 1 |
| Gemcitabine | 0 | 0 | 7 |
| Vinflunine | 0 | 0 | 3 |
| Cabozantinib | 0 | 1 | 2 |
Drug classes tested here Immune checkpoint inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 1 open · Antimitotic agents 1 open · Antimetabolites 9 · Angiogenesis inhibitors 3
Coming up
16studies finish main data collection within a year2 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Jan 2027Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer · Phase 3 · National Cancer Institute (NCI)
- Oct 2027Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery · Phase 3 · Hans Bahlmann
- Dec 2026Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma · Fox Chase Cancer Center
- Dec 2026Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · National Cancer Institute (NCI)
- Dec 2026Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology · Emory University
- Dec 2026Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer · Tianjin Medical University Second Hospital
- Dec 2026ARID1A and/or KDM6A Mutation and CXCL13 Expression · M.D. Anderson Cancer Center
- Dec 2026Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC · Peking University First Hospital
- Dec 2026Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs · Peking University First Hospital
- Mar 2027A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors · Eli Lilly and Company
Who these studies take
Of the 16 Ureteral Neoplasms studies recruiting now, 11 (69%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (6%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 13 (81%) | 13 (81%) |
| 30 | 16 (100%) | 16 (100%) |
| 40 | 16 (100%) | 16 (100%) |
| 50 | 16 (100%) | 16 (100%) |
| 65 | 16 (100%) | 16 (100%) |
| 75 | 16 (100%) | 16 (100%) |
| 85 | 12 (75%) | 12 (75%) |
Across all 79 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 5% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 79. Browse all 79 → or search them.
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingNCT05614739Phase 114 countries
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 18 countries
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingNCT07667335Phase 1/21 country
- Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI TrialRecruitingNCT06764095Phase 41 country
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruitingNCT050594445 countries
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingNCT05756569Phase 21 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersRecruitingNCT07087860Phase 21 country
- Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic SurgeryRecruitingNCT06349668Phase 31 country
- Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral CancerRecruitingNCT07125547Phase 21 country
- Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaRecruitingNCT06983210Phase 21 country
- Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUCRecruitingNCT065987611 country
- Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCsRecruitingNCT06652022Not applicable1 country
- Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With HematuriaNot yet recruitingNCT064692291 country
- The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological TelesurgeryRecruitingNCT05739812Not applicable1 country
- Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing MicrobiomeRecruitingNCT046255561 country
- Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNARecruitingNCT041974141 country
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyActive, not recruitingNCT05092958Phase 32 countries
- Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 12 countries
- Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT03237780Phase 21 country
- Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerActive, not recruitingNCT03244384Phase 32 countries
- Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 11 country
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 11 country
- Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid TumorsCompletedNCT00479128Phase 11 country
- ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 21 country
- Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung CancersCompletedNCT01846520Not applicable1 country
- Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 21 country
- Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryActive, not recruitingNCT02812420Early Phase 11 country
- A Genotype-Phenotype Urothelial Cancer RegistryActive, not recruitingNCT009025901 country
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00942331Phase 32 countries
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 17 countries
- Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial CarcinomaActive, not recruitingNCT032910281 country
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerTerminatedNCT03288545Phase 1/26 countries
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial CarcinomaActive, not recruitingNCT04004442Phase 11 country
- Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaActive, not recruitingNCT04848519Phase 21 country
- A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)CompletedNCT03474107Phase 319 countries
- Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder CancerWithdrawnNCT05687721Phase 1/21 country
- Afatinib in Advanced Refractory Urothelial CancerTerminatedNCT02122172Phase 21 country
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT040284791 country
- A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03219333Phase 28 countries
- A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerCompletedNCT02443324Phase 16 countries
- Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 21 country
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerCompletedNCT01326871Phase 1/21 country
- Urine DNA Methylation Detection for Hematuria EvaluationStatus unknownNCT064279931 country
- Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesCompletedNCT03590054Phase 11 country
- Lymphadenectomy in Urothelial CarcinomaSuspendedNCT02607709Not applicable1 country
- UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearchCompletedNCT02643043Not applicable1 country
- Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI StudyTerminatedNCT04398368Phase 21 country
- Rucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03397394Phase 26 countries
- Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerCompletedNCT03617913Phase 21 country